EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma-Reference-Cited by-同舟云学术

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

Published:2012-04-12 Issue:3 Volume:35 Page:189-196
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Smits Alexander J. J.,Kummer J. Alain,Hinrichs John W. J.,Herder Gerarda J. M.,Scheidel-Jacobse Karen C.,Jiwa N. Mehdi,Ruijter T. Emiel G.,Nooijen Peet T. G. A.,Looijen-Salamon Monica G.,Ligtenberg Marjolijn J. L.,Thunnissen Frederik B.,Heideman Daniëlle A. M.,de Weger Roel A.,Vink Aryan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13402-012-0078-4

Reference33 articles.

1. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962–972 (2008)

2. N.C. Bae, M.H. Chae, M.H. Lee, K.M. Kim, E.B. Lee, C.H. Kim et al., EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet. Cytogenet. 173, 107–113 (2007)

3. B. Gao, Y. Sun, J. Zhang, Y. Ren, R. Fang, X. Han et al., Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J. Thorac. Oncol. 5, 1130–1135 (2010)

4. J.L. Marks, M.D. McLellan, M.F. Zakowski, A.E. Lash, Y. Kasai, S. Broderick et al., Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2, e426 (2007)

5. G.J. Riely, W. Pao, D. Pham, A.R. Li, N. Rizvi, E.S. Venkatraman et al., Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839–844 (2006)

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets;Therapeutic Advances in Medical Oncology;2024-01

2. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis;Medicine;2023-11-17

3. In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer;Journal of Biomolecular Structure and Dynamics;2023-08-30

4. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study;Lung Cancer;2022-05

5. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands;European Journal of Cancer;2022-04